stockrowPalvella Therapeutics, Inc.
PVLA Healthcare Biotechnology
Palvella Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $25.9 million.
- EPS
- −76.7%
- Free cash flow
- −136.4%
Quarter to June 2026, against a year earlier
Follow PVLA
Alert me
Palvella Therapeutics, Inc. (PVLA) P/B ratio
As of 5 November 2026, Palvella Therapeutics, Inc. (PVLA) trades at a P/B ratio of 10.4×. Over the past ten years it has ranged from 0.0× (March 2024) to 73.5× (December 2017); the current reading is higher than 86% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
| FY2022 | 2.9× | (39.78%) |
| FY2021 | 4.8× | 9.50% |
| FY2020 | 4.4× | 23.01% |
| FY2019 | 3.6× | 0.94% |
| FY2018 | 3.5× | (88.03%) |
| FY2017 | 29.5× | 1,123.94% |
| FY2016 | 2.4× | (4.58%) |
| FY2015 | 2.5× | — |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Mar 2024 | 1.2× | — |
| Dec 2023 | 0.0× | — |
| Sep 2023 | 0.9× | 157.77% |
| Jun 2023 | 0.4× | (92.39%) |
| 33 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| BHVN Biohaven Ltd. compare | n/m |
| CLDX Celldex Therapeutics, Inc. compare | 3.1× |
| AUPH Aurinia Pharmaceuticals Inc compare | 3.3× |
| IMNM Immunome, Inc. compare | 3.9× |
| VERA Vera Therapeutics, Inc. compare | 5.3× |
| PHVS Pharvaris N.V. compare | 6.4× |
| ADMA ADMA Biologics Inc compare | 6.7× |
| VCEL Vericel Corporation compare | 6.8× |
| PVLA Palvella Therapeutics, Inc. | 10.4× |
| Biotechnology industry median | 2.0× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on PVLA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement